ST
STAB.US Statera Biopharma Inc
- Market cap
- USD 7.14K
- P/E
- -
- P/B
- 0.16x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is STAB.US undervalued?
Graham numberThe Graham number of Statera Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Statera Biopharma Inc fundamental analysis
No fundamental analysis for Statera Biopharma Inc yet.
Statera Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Statera Biopharma Inc
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, i…
Full company profileStatera Biopharma Inc financial statements
Statera Biopharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | - | - | 7.59M | 47.1M | 41.6M | 0.00 | 1.49M |
| Gross Profit | - | - | - | - | - | 1.91M | 15.1M | 11.5M | -488K | -488K |
| Operating Income | -23.1B | -14.4B | -10.8M | -6.36M | -5.60M | -4.80M | -2.81M | -10.5M | -30.7M | -98.3M |
| EBITDA | -23.1B | -14.4B | -10.8M | -6.36M | -5.60M | -4.80M | -3.10M | -11.0M | -30.5M | -171M |
| Net Income | -17.3B | 1.63B | -12.6M | -2.66M | -9.71M | -3.61M | -3.35M | -13.2M | -102M | -174M |
| EPS | -363 | 0.60 | -1.79 | -0.24 | -0.87 | -0.32 | -0.13 | -0.52 | -2.87 | -4.97 |
| Balance Sheet | ||||||||||
| Total Assets | 14.7B | 3.55B | 20.9M | 16.0M | 9.63M | 4.53M | 1.65K | 1.04M | 21.2M | 21.2M |
| Total Liabilities | 13.1B | 4.55B | 5.84M | 3.11M | 2.22M | 920K | 1.52M | 4.69M | 22.7M | 22.7M |
| Shareholders' Equity | -9.52B | -1.00B | 9.89M | 7.52M | 2.20M | -1.45M | -4.21M | -3.66M | -1.51M | -1.57M |
| Cash & Short-term Investments | 10.4B | 3.67B | 19.6M | 15.2M | 8.79M | 4.12M | 1.58M | 594K | 1.84M | 1.98M |
| Total Debt | 7.21B | 7.33B | - | - | - | - | 1.80M | 2.61M | - | 16.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -23.1B | -14.5B | -12.1M | -5.04M | -6.61M | -4.61M | -240K | -5.08M | -28.2M | -28.2M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 257K | 2.12M | 9.64K | 183K | 183K |
| Free Cash Flow | -23.1B | -14.5B | -12.1M | -5.04M | -6.61M | -4.61M | -240K | -5.09M | -28.4M | -28.4M |
| Ratios | ||||||||||
| ROE | - | - | -127.8% | -35.3% | -441.3% | - | - | - | - | - |
| ROA | -117.5% | 45.9% | -60.5% | -16.7% | -100.8% | -79.7% | -202,924.5% | -1,277.1% | -481.1% | -823.9% |
| Net Profit Margin | - | - | - | - | - | -47.6% | -7.1% | -31.8% | - | -11,728.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Statera Biopharma Inc dividends
Statera Biopharma Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:20 on Jan 28, 2015.
Who owns Statera Biopharma Inc
Top institutions holding STAB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Acadian Asset Management LLC | 212K | 0.30% | -51.29% | Mar 2023 |
| TUCKER ASSET MANAGEMENT LLC | 1.00K | 0.00% | 0.00% | Mar 2023 |
| Royal Bank of Canada | 217.00 | 0.00% | +2,311.11% | Dec 2022 |
| CWM, LLC duplicate | 150.00 | 0.00% | 0.00% | Dec 2022 |
| IFP Advisors, LLC | 87.00 | 0.00% | -85.18% | Mar 2023 |
| UMB Bank NA | 5.00 | 0.00% | 0.00% | Mar 2023 |
| State Street Corporation | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Sandhill Capital Partners LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Archer Investment Corporation | 0.00 | 0.00% | -100.00% | Mar 2023 |
| CI Private Wealth LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Millennium Management LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Ergoteles LLC | 0.00 | 0.00% | -100.00% | Mar 2023 |
| Two Sigma Investments LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Dec 2022 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Mar 2023 |
Statera Biopharma Inc company profile
- Company name
- Statera Biopharma Inc
- Ticker
- STAB.US
- Exchange
- USA Stocks
- Listed since
- Jul 25, 2006
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- 4333 Corbett Drive,, Fort Collins, CO, United States, 80525
- Phone
- 888 613 8802
- Website
- staterabiopharma.com
About Statera Biopharma Inc
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.
Statera Biopharma Inc management
2- Dr. Blake Hawley D.V.M., M.B.A.Executive Chairman · born 1965
- Mr. Christopher ZoshExecutive VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer · born 1976